The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Anna Spreafico
No relevant relationships to disclose
Amit M. Oza
No relevant relationships to disclose
Blaise Clarke
No relevant relationships to disclose
Helen Mackay
No relevant relationships to disclose
Patricia Shaw
No relevant relationships to disclose
Golnar Rasty
No relevant relationships to disclose
Marcus O. Butler
No relevant relationships to disclose
Neesha C. Dhani
No relevant relationships to disclose
Stephanie Lheureux
No relevant relationships to disclose
Michelle Wilson
No relevant relationships to disclose
Stephen Welch
No relevant relationships to disclose
Lillian L. Siu
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Tong Zhang
No relevant relationships to disclose
Celeste Yu
No relevant relationships to disclose
Geeta D Krishna
No relevant relationships to disclose
Helen Chow
No relevant relationships to disclose
Tracy Stockley
No relevant relationships to disclose
Suzanne Kamel-Reid
No relevant relationships to disclose
Philippe L. Bedard
Consultant or Advisory Role - Novartis; Roche; Sanofi
Research Funding - GlaxoSmithKline; Novartis; Roche; Sanofi